Previous 10 | Next 10 |
home / stock / vphif / vphif news
Valeo Pharma's Redesca® and Redesca HP® to Be Covered Under the Ontario Public Drug Benefit Program PR Newswire Ontario represents 37% of the Canadian low molecular weight heparin market Additional provincial coverage expected to follow ...
Valeo Pharma Upsizes And Closes $6.6 Million Non-Brokered Private Placement Canada NewsWire Valeo insiders participation of $2.6 million MONTRÉAL, April 27, 2021 /CNW Telbec/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Val...
Valeo Pharma Announces Commercial Launch of Redesca™ and Redesca HP™ PR Newswire Shipments have commenced across Canada National sales coverage in full deployment through a dedicated key account managers team Private and public reimb...
Valeo Pharma (VPHIF) launched a non-brokered private placement of up to 4K unsecured non-convertible debentures units at $1K per debenture unit for maximum gross proceeds of $4M.Each debenture unit will consist of one unsecured non-convertible debenture of the company in the principal amount ...
Valeo Pharma Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures Canada NewsWire /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN ...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 8, 2021 – Conditions such as HIV, asthma, hepatitis, and severe migraines affect the quality of life of those living with these conditions. These conditions require patients to tak...
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP® Canada NewsWire MONTREAL , April 6, 2021 /CNW Telbec/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Comp...
Valeo Pharma (VPHIF): Q1 GAAP EPS of -C$0.03.Revenue of C$1.9M (+11.1% Y/Y)Press Release For further details see: Valeo Pharma reports Q1 results
Valeo Pharma Reports its First Quarter 2021 Results and Highlights Canada NewsWire Valeo secured the Canadian rights to Enerzair® Breezhaler® and Atectura® Breezhaler®, two new innovative Asthma therapies Q1-21 net revenues of $1.9 m...
Mr. Steve Saviuk reports VALEO PHARMA INC. ENTERS INTO AN AGREEMENT FOR ENERZAIR BREEZHALER AND ATECTURA BREEZHALER IN CANADA Valeo Pharma Inc. (CSE:VPH) (OTCQB:VPHIF) (FSE: VP2) ("Valeo" or the "Company") has entered into a commercialization and supply agreement with ...
News, Short Squeeze, Breakout and More Instantly...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million rec...
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY Canada NewsWire Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exce...